Ion Beam Applications (IBA) announced that its US subsidiary, Eastern Isotopes, Inc. has begun distributing Iodine-124 (MIBG), an analogue of a biogenic amine precursor, norepinephrine. MIBG has been widely used in its radiolabbeled forms (usually I-123 or I-131) for the evaluation of the cardiac sympathetic nervous system and the diagnosis, treatment planning and radiotherapy of various neuroendocrine malignancies.  IBA expects that I-124 MIBG may be useful for researchers evaluating other types of patients.  The FDA has not evaluated it.

IBA, headquartered in Belgium provides radiopharmaceuticals, notably in the field of Positron Emission Tomography (PET).